Nuveen LLC Purchases Shares of 2,336,628 Amneal Pharmaceuticals, Inc. $AMRX

Key Points

• Nuveen LLC has acquired a new position in Amneal Pharmaceuticals, investing approximately $19.58 million for 2,336,628 shares, representing 0.75% ownership of the company.
• Multiple institutional investors, including Vanguard Group Inc. and Dimensional Fund Advisors, have significantly increased their holdings in Amneal Pharmaceuticals, indicating growing confidence in the company.
• Analysts project growth for Amneal, with a consensus buy rating and an average price target of $11.60, suggesting potential upside for investors.

Nuveen LLC purchased a new stake in shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX - Free Report) during the first quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 2,336,628 shares of the company's stock, valued at approximately $19,581,000. Nuveen LLC owned about 0.75% of Amneal Pharmaceuticals as of its most recent SEC filing.

A number of other institutional investors and hedge funds also recently made changes to their positions in AMRX. GAMMA Investing LLC boosted its holdings in shares of Amneal Pharmaceuticals by 5,975.0% in the first quarter. GAMMA Investing LLC now owns 3,159 shares of the company's stock worth $26,000 after buying an additional 3,107 shares during the last quarter. Headlands Technologies LLC purchased a new position in shares of Amneal Pharmaceuticals in the first quarter worth approximately $31,000. Amalgamated Bank boosted its holdings in shares of Amneal Pharmaceuticals by 33.0% in the first quarter. Amalgamated Bank now owns 5,511 shares of the company's stock worth $46,000 after buying an additional 1,367 shares during the last quarter. GF Fund Management CO. LTD. purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $52,000. Finally, Brevan Howard Capital Management LP purchased a new position in shares of Amneal Pharmaceuticals in the fourth quarter worth approximately $107,000. Hedge funds and other institutional investors own 31.82% of the company's stock.

Analyst Ratings Changes

A number of research firms recently issued reports on AMRX. The Goldman Sachs Group began coverage on shares of Amneal Pharmaceuticals in a report on Friday, June 6th. They issued a "buy" rating and a $12.00 price objective on the stock. Wall Street Zen downgraded shares of Amneal Pharmaceuticals from a "strong-buy" rating to a "buy" rating in a report on Tuesday, May 13th. Five investment analysts have rated the stock with a Buy rating, Based on data from MarketBeat.com, the stock has an average rating of "Buy" and a consensus target price of $11.60.

Insiders Place Their Bets

In other Amneal Pharmaceuticals news, EVP Nikita Shah sold 71,694 shares of the stock in a transaction dated Thursday, August 14th. The shares were sold at an average price of $9.29, for a total transaction of $666,037.26. Following the transaction, the executive vice president directly owned 267,235 shares in the company, valued at $2,482,613.15. This represents a 21.15% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, EVP Andrew S. Boyer sold 279,244 shares of the stock in a transaction dated Wednesday, August 20th. The stock was sold at an average price of $9.38, for a total transaction of $2,619,308.72. Following the transaction, the executive vice president owned 152,426 shares in the company, valued at approximately $1,429,755.88. The trade was a 64.69% decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold a total of 456,374 shares of company stock worth $4,239,042 in the last three months. Corporate insiders own 26.56% of the company's stock.

Amneal Pharmaceuticals Price Performance

Shares of AMRX traded up $0.06 during midday trading on Friday, hitting $9.59. The stock had a trading volume of 1,720,973 shares, compared to its average volume of 1,697,029. The stock's 50 day moving average is $8.38 and its 200 day moving average is $8.01. The firm has a market cap of $3.01 billion, a PE ratio of 959.96 and a beta of 1.11. Amneal Pharmaceuticals, Inc. has a 1 year low of $6.68 and a 1 year high of $9.79.

Amneal Pharmaceuticals (NASDAQ:AMRX - Get Free Report) last posted its quarterly earnings results on Tuesday, August 5th. The company reported $0.23 EPS for the quarter, topping analysts' consensus estimates of $0.17 by $0.06. Amneal Pharmaceuticals had a net margin of 0.12% and a negative return on equity of 189.49%. Amneal Pharmaceuticals has set its FY 2025 guidance at 0.700-0.750 EPS. As a group, equities research analysts expect that Amneal Pharmaceuticals, Inc. will post 0.53 earnings per share for the current fiscal year.

About Amneal Pharmaceuticals

Amneal Pharmaceuticals, Inc, together with its subsidiaries, develops, manufactures, markets, and distributes generics, injectables, biosimilars, and specialty branded pharmaceutical products worldwide. The company operates through three segments: Generics, Specialty, and AvKARE. The Generics segment offers immediate and extended release oral solid, powder, liquid, sterile injectable, nasal spray, inhalation and respiratory, biosimilar, ophthalmic, film, transdermal patch, and topical products.